What's Happening?
Corcept Therapeutics Incorporated has presented new data from its CATALYST and MOMENTUM trials at the American Diabetes Association's 86th Scientific Sessions. The data highlights the role of hypercortisolism in difficult-to-control type 2 diabetes and resistant
hypertension, and the potential benefits of cortisol modulation treatment. The CATALYST trial screened over 1,000 patients with difficult-to-control type 2 diabetes, finding that 24% had hypercortisolism. Patients treated with Korlym showed significant improvements in metabolic parameters, including reductions in hemoglobin A1c, body weight, and waist circumference. The MOMENTUM trial also found a high prevalence of hypercortisolism in patients with resistant hypertension.
Why It's Important?
The findings from Corcept's trials underscore the potential of cortisol modulation as a treatment strategy for patients with type 2 diabetes who do not respond to standard therapies. This approach could improve the management of diabetes and hypertension, conditions that affect millions of Americans. By addressing hypercortisolism, healthcare providers may enhance the effectiveness of existing diabetes treatments, potentially reducing healthcare costs and improving patient outcomes. The research also suggests a need for increased screening for hypercortisolism in patients with resistant metabolic conditions.
What's Next?
Corcept's research may lead to broader adoption of cortisol modulation treatments in clinical practice. The company hopes that the findings will encourage more healthcare providers to screen for hypercortisolism and consider cortisol-directed therapies for patients with difficult-to-control diabetes and hypertension. Further studies and clinical trials could expand the understanding of cortisol's role in metabolic disorders and refine treatment protocols.
